GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Encision Inc (OTCPK:ECIA) » Definitions » Cash, Cash Equivalents, Marketable Securities

ECIA (Encision) Cash, Cash Equivalents, Marketable Securities : $0.35 Mil (As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Encision Cash, Cash Equivalents, Marketable Securities?

Encision's quarterly cash, cash equivalents, marketable securities declined from Jun. 2024 ($0.27 Mil) to Sep. 2024 ($0.23 Mil) but then increased from Sep. 2024 ($0.23 Mil) to Dec. 2024 ($0.35 Mil).

Encision's annual cash, cash equivalents, marketable securities declined from Mar. 2022 ($0.95 Mil) to Mar. 2023 ($0.19 Mil) and declined from Mar. 2023 ($0.19 Mil) to Mar. 2024 ($0.04 Mil).


Encision Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Encision's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Encision Cash, Cash Equivalents, Marketable Securities Chart

Encision Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 1.47 0.95 0.19 0.04

Encision Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.04 0.27 0.23 0.35

Encision Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Encision  (OTCPK:ECIA) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Encision Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Encision's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Encision Business Description

Industry
Traded in Other Exchanges
N/A
Address
6797 Winchester Circle, Boulder, CO, USA, 80301
Encision Inc is a medical device company. The company develops and markets technology that provides unprecedented outcomes and patient safety in minimally invasive surgery. The company has established and developed AEM (Active Electrode Monitoring) technology and surgical instruments which provide surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The segments of the company are Product and Service. Product designs develops, manufactures and markets patented surgical instruments. Service performs electrical engineering activities for external entities. Maximum revenue is generated from the product segment.
Executives
Robert H Fries director 800 FILLMORE ST, DENVER CO 80206
Gregory J. Trudel director, officer: CEO 5241 RIMROCK LANE, FORT COLLINS CO 80526
Peter D Geary officer: VP of Operations 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Jason E Johnson officer: VP Sales 17752 WEDGEWOOD LANE, PRIOR LAKE MN 55372
Patrick R Dixon director 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Brian J Jackman director 6797 WINCHESTER CIRCLE, SUITE 100, BOULDER CO 80301
Von Der Lippe Paul director 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Denise Baker director 6797 WINCHESTER CIRCLE, BOULDER X1 80301
Vern D Kornelsen director, 10 percent owner 4605 S. DENICE DR, ENGLEWOOD CO 80111
Partners Lllp Cmed 10 percent owner
Patrick W Pace director 3701 SOARING EAGLE, AUSTIN TX 78746
Michael Biggs officer: VP Engineering 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Brad Greathouse officer: VP RA/QA 6797 WINCHESTER CIRCLE, BOULDER CO 80301
Valerie Ray officer: VP of Operations 6797 WINCHESTER CIRCLE, BOULDER CO 80301
David W Newton director, officer: VP Technology 8099 NORTH 63RD STREET, LONGMONT CO 80503

Encision Headlines

From GuruFocus

Encision Reports Fourth Quarter Fiscal Year 2019 Results

By PRNewswire PRNewswire 05-14-2019

Encision Reports Second Quarter Fiscal Year 2019 Results

By PRNewswire PRNewswire 11-06-2018

Encision Reports Third Quarter Fiscal Year 2021 Results

By PRNewswire PRNewswire 02-04-2021

Encision Signs Supplier Agreement with Human Xtensions

By ACCESSWIRE ACCESSWIRE 02-28-2023

Encision Reports Fourth Quarter Fiscal Year 2020 Results

By PRNewswire PRNewswire 05-14-2020

Encision Reports First Quarter Fiscal Year 2022 Results

By PRNewswire PRNewswire 08-09-2021

Encision Reports First Quarter Fiscal Year 2019 Results

By PRNewswire PRNewswire 08-02-2018

Encision Reports Second Quarter Fiscal Year 2022 Results

By PRNewswire PRNewswire 11-10-2021